Masked Polyamine Conjugates for Polynucleotide Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transfection reagents for delivering polynucleotides into cells are hindered by toxicity and poor bioavailability due to their cationic charge, leading to adverse serum interactions and ineffective targeting in vivo, while existing formulations are often too large to access cells other than blood vessel cells.
Innovation Solution
A composition of reversibly masked membrane-active polyamines conjugated to polynucleotides via labile covalent linkages, which are modified by masking agents to inhibit membrane activity and improve biodistribution, allowing for targeted and controlled release of the polynucleotides within cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cationic transfection reagents are used to deliver polynucleotides, then membrane destabilization and cell entry are improved, but toxicity and serum interactions worsen
Solution Approach 1:
The patent changes the charge parameter from cationic to neutral or anionic by incorporating negatively charged lipids or polymers, thereby eliminating serum protein binding and toxicity while maintaining membrane interaction capability through non-electrostatic mechanisms
Solution Approach 2:
The patent creates composite transfection agents combining neutral/anionic lipids with polynucleotides, achieving effective delivery without the harmful effects of cationic charges, including reduced serum interactions and improved biocompatibility
2Reliability
If cationic transfection reagents are used, then polynucleotide binding is improved, but bioavailability worsens
Solution Approach 1:
The patent changes the charge parameter from positive to neutral or negative, eliminating electrostatic repulsion with serum proteins and improving circulating bioavailability while maintaining nucleic acid binding through alternative mechanisms such as hydrophobic interactions or steric effects
3Reliability
If membrane active polyamines are used for delivery, then cell penetration is improved, but toxicity worsens
Solution Approach 1:
The patent changes the charge parameter from cationic to neutral or anionic, maintaining membrane interaction capability through non-electrostatic mechanisms while eliminating the toxicity associated with cationic polyamines and their serum interactions
4Volume of moving object
If transfection complexes are made small for in vivo delivery, then cell access is improved, but complex stability worsens
Solution Approach 1:
The patent creates stable small complexes by combining neutral/anionic lipids with polynucleotides, achieving both compact size for tissue penetration and stability through non-electrostatic binding mechanisms that prevent aggregation and maintain structural integrity in physiological conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and targeted delivery of polynucleotides to cells while minimizing toxicity and improving bioavailability, achieving effective gene knockdown and protein expression in specific tissues.
Implementation Method 1
The polyamine is modified by attachment to one or more masking agents via one or more first reversible labile covalent linkages
Implementation Method 2
The first and second labile covalent linkages may comprise labile bonds that are cleaved under the same or similar conditions
Data Source
AI summary
The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible or labile linkages connecting component parts provides for physiologically responsive activity modulation.